KALA BIO, Inc.
KALA BIO, Inc. (KALA): 3 pipeline candidates · ~10 mo cash runway · 1 clinical trial. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
9.8 months
D/E 0.14 · 0% dilution
Lead: Phase 2
3 candidates
N/A
N/A
A transparent, data-derived signal for KALA BIO, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$52.9M
Cash
$1.8M
Quarterly Burn
$2.9M
Runway
9.8 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (3 candidates)
| Drug | Phase |
|---|---|
| KPI-012 | Phase 2 |
| KPI-012 Vehicle | Phase 2 |
| KPI-014 | Phase 2 |
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
24
Total value held
$244K
| Holder | Shares | Value |
|---|---|---|
| renaissance technologies llc | 417,517 | $72K |
| citadel advisors llc | 281,650 | $49K |
| geode capital management, llc | 261,061 | $45K |
| adar1 capital management, llc | 141,480 | $24K |
| vanguard capital management llc | 121,098 | $21K |
| jane street group, llc | 36,000 | $6K |
| vanguard fiduciary trust co | 29,628 | $5K |
| state street corp | 28,576 | $5K |
| grant private wealth management inc | 20,000 | $3K |
| lpl financial llc | 17,229 | $3K |
Showing top 10 of 24 institutional holders of KALA BIO, Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in KALA BIO, Inc.'s pipeline?
KALA BIO, Inc. (KALA) has 3 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is KALA BIO, Inc.'s lead drug candidate?
KALA BIO, Inc.'s most advanced tracked candidate is KPI-012 (Phase 2) for Persistent Corneal Epithelial Defect.
What is KALA BIO, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, KALA BIO, Inc. has approximately 9.8 months of cash runway.
What is KALA BIO, Inc.'s market capitalization?
KALA BIO, Inc.'s market capitalization is approximately $52.9M.
Who is the CEO of KALA BIO, Inc.?
Mr. Avi Minkowitz is the chief executive officer of KALA BIO, Inc. (KALA).
Get the full picture on KALA BIO, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.